Search the Newsreel

Novo Nordisk Suffers Another Pipeline Setback

This article first appeared on GuruFocus. Novo Nordisk (NVO, Financials), the Danish pharmaceutical company, saw its shares fall sharply Friday after a late-stage trial of its experimental heart medicine failed to meet its primary endpoint. Warning! GuruFocus has detected 4 Warning Sign with NVO. …

Novo Nordisk Stock Falls 7% as ZEUS Trial Fails

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) fell 7.42% in Copenhagen after reporting that ziltivekimab failed to reduce major adverse cardiovascular events in the ZEUS phase 3 trial. The hazard ratio against placebo was 0.99, meaning no measurable difference, with a confidence …

Novo Nordisk stock tumbles 10% as key trial misses goal

Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial. The Danish company reported that its Phase 3 ZEUS trial showed no reduction in major adverse …

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisktoday announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive …

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Novo Nordisk's stock declined by 9% after its late-stage ZEUS trial for ziltivekimab, a drug targeting heart and kidney disease and inflammation, failed. The trial, involving 6,300 patients, aimed to reduce cardiovascular-related deaths, nonfatal heart attacks, and strokes. This setback adds to the company's …

Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail

Novo Nordisk's ziltivekimab, an IL-6 antibody, failed to meet its primary endpoint in the Zeus phase 3 trial for chronic kidney disease, atherosclerotic cardiovascular disease, and inflammation. This setback significantly dampens the drug's prospects, which analysts had projected to generate blockbuster sales. The company …

Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results

Novo Nordisk's U.S.-listed shares fell sharply premarket after its heart drug ziltivekimab failed to meet expectations in a Phase 3 trial. The drug, aimed at inflammatory conditions, did not reduce major adverse cardiovascular events in patients despite showing target engagement. While this outcome won't …

FinVolution Group (FINV) Institutional Confidence

FinVolution Group (FINV) has an institutional shareholding score of 5.00, placing it 20th in the Financial Technology (Fintech) & Infrastructure industry. The institutional shareholding proportion is 53.82%, a 10.14% decrease quarter-over-quarter. Sarah Ketterer is the largest institutional shareholder, holding 1.97M shares, despite a nearly …

FinVolution Group (FINV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for FinVolution Group (FINV), assigning it a score of 5.01 and ranking it 15th out of 76 in the Financial Technology (Fintech) & Infrastructure industry. Key metrics include a beta of 0.38, indicating lower volatility compared to the …

Novo Nordisk (CPSE:NOVO B) Is Up 5.9% After EU Wegovy Pill Approval And US Access Deal

Earlier this month, the European Commission granted marketing authorisation for Novo Nordisk's once-daily Wegovy oral pill for obesity across all EU member states, while Crux announced a collaboration with the company to expand affordable, simplified access to authentic anti-obesity medications like Wegovy for US …

Novo Nordisk (CPSE:NOVO B) Teams Up With Crux To Expand Wegovy Access

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) has partnered with Crux to expand access to anti obesity medicines such as Wegovy for employer health plans in …

Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court

A U.S. District Judge in New Jersey has ruled that Novo Nordisk must face fraud allegations from shareholders regarding its weight loss drug CagriSema. Shareholders claim Novo withheld crucial information about protocol changes in a Phase 3 study, leading them to purchase shares at …

FINV|FinVolution Group|Price:4.930|Chg%:+0.070

This article provides a comprehensive stock analysis of FinVolution Group (FINV) by TradingKey, highlighting its healthy fundamentals, high growth potential, and fair valuation within the Financial Technology industry. The stock is rated as a "Strong Buy" by analysts with a target price of $7.27, …

US judge says Novo Nordisk must face lawsuit over CagriSema

A US judge has ruled that Novo Nordisk must face certain allegations in court regarding a class-action lawsuit. The lawsuit claims the company defrauded investors with misleading comments about the REDEFINE-1 trial for its obesity drug, CagriSema, particularly concerning dosing information and "overwhelmingly positive …

Novo Nordisk (NYSE:NVO) Stock Looks Undervalued On Cash Flow And Earnings

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). Since launch, Novo Nordisk has steadily expanded the commercial opportunity …

Tibooburra Gold Project Update

HIGHLIGHTS Novo has moved to the second stage and is progressing exploration at the Tibooburra Gold Project in NSW through a Farm-in/JV with Manhattan Gold Corporation Limited (ASX: MHC).Novo will commence a ~2,700 m RC program at Tibooburra, with drilling to occur at the …

FinVolution Group Sponsored ADR Class A Revenue Breakdown – SWB:PP3

FinVolution Group (SWB:PP3) reported total revenue of €1.65 billion last year (2025). The company's primary revenue driver was its Loan Facilitation segment, contributing €613.11 million, slightly down from €630.09 million in the prior year. Geographically, China was the largest contributor to revenue, accounting for …

Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing

Novo Nordisk (NVO) closed at $50.96 in the latest trading session, marking a +2.6% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 1.03%, while the tech-heavy Nasdaq lost 0.22%. The …

Novo Nordisk’s ZEUS Trial Reaches Completion: What It Could Mean for NVO Investors

Novo Nordisk's Phase 3 ZEUS trial, investigating ziltivekimab for cardiovascular outcomes in high-risk patients, has completed. This antibody aims to reduce heart events in individuals with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation. The trial's success could expand Novo Nordisk's market beyond …

Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight

The congestive heart failure market is expected to witness steady growth over the coming years, driven by the rising prevalence of cardiovascular diseases, an aging global population, and increasing awareness of early diagnosis and disease management. In addition, the expected launch of emerging therapies …

Lucid Capital Markets initiates Envoy Medical stock with buy rating By Investing.com

Lucid Capital Markets has initiated coverage on Envoy Medical (NASDAQ:COCH) with a buy rating and a price target of $2.00, representing a 203% upside. The firm highlighted Envoy’s fully implanted cochlear implant device, Acclaim, which offers 24/7 hearing without external components and has received …

FinVolution Group (FINV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of FinVolution Group (FINV), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests that the stock is currently suitable for range-bound swing trading, with a neutral signal based …

FinVolution Group (FINV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for FinVolution Group (FINV). However, it states that relevant data regarding business segments and regional revenue and profit contribution have not been disclosed by the company yet. The article primarily displays general financial information and market …

Why Novo Resources Corp stock surged yesterday

Novo Nordisk Boosts Treasury Stock as 2026 Share Buyback Passes DKK 7.1 Billion

Novo Nordisk has notably increased its treasury stock as its B-share buyback program for 2026 has exceeded DKK 7.1 billion, representing 1.0% of its share capital. The company launched this repurchase program as part of a larger plan to buy back up to DKK …

Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy (NYSE:NVO)

Novo Nordisk (NVO) has received a "Modest Buy" rating with a raised price target of $80, primarily driven by the rapid market adoption of its oral Wegovy. The drug has achieved over 3 million prescriptions in five months, largely from new GLP-1 patients, indicating …

Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings (NYSE:NVO)

FinVolution Group (FINV) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of FinVolution Group's (FINV) dividend payouts and related event timelines. It details the company's past cash dividends, including the gross amount, record date, payment date, and ex-dividend date, spanning from 2020 to projected dates in 2026. The company …

FinVolution Group (FINV) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of FinVolution Group (FINV), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings for key investors. The report also …

Novo Nordisk: Initiating Buy, Calling The Bottom (NYSE:NVO)

Willow Tree Research initiates coverage on Novo Nordisk (NVO) with a "BUY" rating and a $68 price target, believing its current valuation presents an attractive entry point. The expansion of the treated obesity market by oral Wegovy, along with a robust pipeline, is expected …

Eli Lilly and Novo Nordisk Are Locked in a Legal War. Don’t Lose Sight of the Main Event.

Eli Lilly and Novo Nordisk are currently engaged in a legal dispute, but the financial community is more focused on a larger underlying narrative. Eli Lilly is expected to seek regulatory approval for its drug retatrutide in the first quarter of 2027.

Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts

Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Lilly had run misleading advertisements about its weight loss drug when it came to touting their superior …

FinVolution Group (FINV) Q1 2026 Earnings: EPS Beats with No Estimate, Shares Edge Higher - Profit Cycle Analysis

Finvolution Group (PP3) Q4 2023 Earnings Report - Results, Call & Slides

Finvolution Group (PP3) announced its Q4 2023 earnings, reporting an actual EPS of €0.25, matching the previous year's performance, but missing revenue expectations with €391.23M against an anticipated €424.10M. The company experienced a 4.03% year-over-year revenue growth. The next earnings report is estimated for …

Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug Advertising

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues …